Q&A Genmab 2019-05-13

	13/5 15:08 af Andrew Carlsen	We continue to believe that the MAIA approval will arrive in Q219 and the uptake will be immediate so still confident on our 2019 sales guidance..
	13/5 15:07 af Andrew Carlsen	Well we have reiterated our 2019 guidance which is based on our Darzalex sales guidance of USD 3bn...
	13/5 15:05 af Helge Larsen/PI-redaktør	Can you tell us about your guiding for the hole year?
	13/5 15:04 af Andrew Carlsen	In conclusion a very busy Q119, we believe..
	13/5 15:03 af Andrew Carlsen	Proprietary Pipeline: TV patient enrollment completed Ph II innovaTV 204 study in recurrent and/or metastatic cervical cancer TV FPD Ph I/II innovaTV 206 study in Japan in cervical cancer TV FPD Ph I/II innovaTV 205 study in comb with bevacizumab, pembrolizumab or carboplatin for recurrent cervical cancer CTA filed for DuoBody-CD40x4-1BB and for DuoBody-PD-L1x4-1BB…
	13/5 15:03 af Andrew Carlsen	Daratumumab: US approval split dose regimen US & EU regulatory submissions based on CASSIOPEIA US & EU regulatory submissions based on MAIA Positive topline Phase III COLUMBA data SC vs IV – met primary endpoints MorphoSys patent case ended…
	13/5 15:02 af Andrew Carlsen	DARZALEX Q1 net sales were USD 629 million vs USD 432 million in Q1 18, driven by the continued strong uptake in the US, EU and Japan – resulting in royalties of DKK 502M – we firmly expect to reach net sales USD 3 billion in 2019…
	13/5 15:02 af Andrew Carlsen	We are maintaining our 2019 financial guidance, which was initially published on Feb. 20…
	13/5 15:01 af Andrew Carlsen	During Q1, we experienced solid business progress as we continue to invest in achieving our 2025 vision and accelerating our world-class product pipeline…
	13/5 15:01 af Andrew Carlsen	We are pleased to be well on track with the company’s financial results for the quarter ended March 31, 2019 and with the excellent progress with DARZALEX…
	13/5 15:01 af Helge Larsen/PI-redaktør	Can you give us a short-term update on key figures and important events in Q1?
	13/5 15:00 af Andrew Carlsen	Hello everyone and thank you for allowing me to have this chat instead of CEO Jan and CFO David..
	13/5 14:59 af Helge Larsen/PI-redaktør	Andrew Carlsen, Senior Director, IR . Welcome to Q&A here on ProInvestor.com. We are very happy to have you here and ready to answer questions from our investors.
	13/5 14:58 af Andrew Carlsen	Hello Helge, This is Andrew from Genmab
	13/5 14:58 af Helge Larsen/PI-redaktør	Andrew. Are you online?
	13/5 09:42 af Helge Larsen/PI-redaktør	Denne session starter kl. 15.